Teva Pharmaceutical Stock Declines Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy TEVA?
Teva Pharmaceutical's stock fell by 5.60% and hit a 20-day low, reflecting broader market challenges as the Nasdaq-100 and S&P 500 both experienced significant declines of over 2%.
The decline in Teva's stock price is primarily attributed to sector rotation, as the company faces increasing competition in its generics business and a cautious investor sentiment regarding its transition to specialty pharmaceuticals. Despite a recent earnings report showing strong revenue growth and a positive outlook for its drug candidate duvakitug, the overall market environment has led to a negative reaction in the stock price.
Investors are closely monitoring Teva's strategic shift and its ability to navigate the competitive landscape. While the company has potential for future growth, the current market conditions and investor caution may continue to impact its stock performance in the near term.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TEVA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TEVA
Wall Street analysts forecast TEVA stock price to rise
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 31.520
Low
29.00
Averages
35.71
High
40.00
Current: 31.520
Low
29.00
Averages
35.71
High
40.00
About TEVA
Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ProShares Short MSCI EAFE ETF Sees 36.6% Inflow Surge
- Significant Inflow Growth: The ProShares Short MSCI EAFE ETF added 240,000 units this week, resulting in a 36.6% increase in outstanding units, indicating strong investor demand and reflecting concerns over international stock downside risks.
- Positive Market Response: The inflow growth suggests that investors are seeking strategies to hedge against international market volatility, particularly amid increasing global economic uncertainty, which may attract more capital into the fund.
- Increased Investor Confidence: With the rise in inflows, the ProShares Short MSCI EAFE ETF may garner more attention from institutional investors, enhancing its market position and liquidity, thereby increasing its significance in investment portfolios.
- ETF Market Dynamics: The performance of this ETF aligns with overall ETF market trends, demonstrating a preference among investors for short-term hedging tools, which could lead to increased inflows for similar products and drive growth across the industry.
See More
Long-Term Investment Opportunities Amid Market Volatility
- Brookfield Corporation Undervalued: Brookfield Corporation, with a market cap of $105 billion, has seen its stock drop 2.99% amid market volatility; however, it is projected to achieve over 20% earnings growth in the next five years, potentially closing the valuation gap of its holdings and driving stock appreciation.
- SSR Mining Benefits from Rising Gold Prices: As geopolitical tensions escalate, gold prices have surged again, leading SSR Mining's stock to hit new highs; with adjusted earnings expected to grow significantly due to high gold prices, the stock currently trades at less than 9 times forward earnings, indicating strong investment potential.
- Teva Pharmaceuticals' Ongoing Transformation: Israel-based Teva Pharmaceuticals is transitioning from a generic drugmaker to a branded pharmaceutical company, with its branded drug business growing at a mid-double-digit rate; as its drug pipeline advances, steady sales and profitability growth are expected, with a current forward P/E of 12.5 that could rise to the mid-teens.
- Market Trends and Investment Opportunities: Despite multiple challenges in the market, certain stocks are benefiting from trends like rising gold prices and the adoption of generative AI; even with just $1,000, investors can consider these stocks, which may yield substantial long-term returns.
See More
Comparing Turnarounds: Pfizer vs. Teva
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.3%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it more appealing to income-focused investors.
- Pfizer's Challenges and Responses: Facing key patent expirations and setbacks in new drug development, Pfizer has strategically acquired a promising GLP-1 drug candidate, demonstrating its resilience and ability to thrive amid industry fluctuations.
- Teva's Turnaround Risks: Teva is undergoing a significant business transformation to include both generics and new drugs, which increases its risk profile, especially as it currently does not offer dividends to attract income-seeking investors.
- Investor Choice: For turnaround investors, Pfizer may represent a superior option, particularly for those who value dividends, as Teva's business overhaul presents greater challenges compared to the typical industry headwinds Pfizer is navigating.
See More
Druckenmiller Cuts Pharma and Semiconductor Holdings
- Selling Top Performers: In his latest 13F filing, Druckenmiller reduced his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% cut, and also sold 222,000 shares of Taiwan Semiconductor Manufacturing (TSMC), a 29% reduction, indicating a cautious outlook on the future performance of these stocks.
- Teva's Financial Improvement: Under CEO Richard Francis, Teva has focused on high-margin novel drug development, leading to significant sales growth, with its stock price doubling since Druckenmiller's initial investment in Q3 2024, reflecting improved financial flexibility after years of cost-cutting and asset sales.
- TSMC's AI Advantage: TSMC, the world's leading chip fabricator, has also seen its stock price double since Druckenmiller opened a position, benefiting from its chip technology being a staple in AI-accelerated data centers, highlighting its critical role in the rapidly evolving tech landscape.
- New Investment Focus: Druckenmiller's 13F report revealed a purchase of 5,495,600 shares of the State Street Financial Select Sector SPDR ETF (XLF), making it his fund's second-largest holding, signaling optimism about the U.S. economic recovery, despite the Federal Reserve's easing cycle since September 2024, which could impact financial stocks' performance.
See More
Druckenmiller Reduces Stakes in Pharma and Semiconductor Stocks
- Pharmaceutical Stake Reduction: Druckenmiller cut his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% reduction, reflecting a profit-taking strategy after significant stock appreciation, indicating a cautious outlook on the pharmaceutical sector's future.
- Semiconductor Stake Cut: He also reduced his position in Taiwan Semiconductor by 222,000 shares, a 29% decrease, likely due to concerns over the stock's overheated performance amid the AI revolution, showcasing his sensitivity to market fluctuations.
- ETF Investment Increase: Druckenmiller purchased 5,495,600 shares of the State Street Financial Select Sector SPDR ETF, making it the fund's second-largest holding, signaling optimism about the U.S. economic recovery, particularly as rising interest rates could enhance financial sector profitability.
- Portfolio Dynamics: With an average holding period of 7.5 months for securities in his portfolio, Druckenmiller demonstrates a flexible investment strategy and rapid responsiveness to market changes, suggesting a keen awareness of future market trends.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
ProShares Short MSCI EAFE ETF Sees 36.6% Inflow Surge
- Significant Inflow Growth: The ProShares Short MSCI EAFE ETF added 240,000 units this week, resulting in a 36.6% increase in outstanding units, indicating strong investor demand and reflecting concerns over international stock downside risks.
- Positive Market Response: The inflow growth suggests that investors are seeking strategies to hedge against international market volatility, particularly amid increasing global economic uncertainty, which may attract more capital into the fund.
- Increased Investor Confidence: With the rise in inflows, the ProShares Short MSCI EAFE ETF may garner more attention from institutional investors, enhancing its market position and liquidity, thereby increasing its significance in investment portfolios.
- ETF Market Dynamics: The performance of this ETF aligns with overall ETF market trends, demonstrating a preference among investors for short-term hedging tools, which could lead to increased inflows for similar products and drive growth across the industry.
See More
Long-Term Investment Opportunities Amid Market Volatility
- Brookfield Corporation Undervalued: Brookfield Corporation, with a market cap of $105 billion, has seen its stock drop 2.99% amid market volatility; however, it is projected to achieve over 20% earnings growth in the next five years, potentially closing the valuation gap of its holdings and driving stock appreciation.
- SSR Mining Benefits from Rising Gold Prices: As geopolitical tensions escalate, gold prices have surged again, leading SSR Mining's stock to hit new highs; with adjusted earnings expected to grow significantly due to high gold prices, the stock currently trades at less than 9 times forward earnings, indicating strong investment potential.
- Teva Pharmaceuticals' Ongoing Transformation: Israel-based Teva Pharmaceuticals is transitioning from a generic drugmaker to a branded pharmaceutical company, with its branded drug business growing at a mid-double-digit rate; as its drug pipeline advances, steady sales and profitability growth are expected, with a current forward P/E of 12.5 that could rise to the mid-teens.
- Market Trends and Investment Opportunities: Despite multiple challenges in the market, certain stocks are benefiting from trends like rising gold prices and the adoption of generative AI; even with just $1,000, investors can consider these stocks, which may yield substantial long-term returns.
See More
Comparing Turnarounds: Pfizer vs. Teva
- Dividend Yield Comparison: Pfizer's dividend yield stands at 6.3%, significantly higher than the S&P 500's 1.1% and the pharmaceutical sector's average of 1.7%, making it more appealing to income-focused investors.
- Pfizer's Challenges and Responses: Facing key patent expirations and setbacks in new drug development, Pfizer has strategically acquired a promising GLP-1 drug candidate, demonstrating its resilience and ability to thrive amid industry fluctuations.
- Teva's Turnaround Risks: Teva is undergoing a significant business transformation to include both generics and new drugs, which increases its risk profile, especially as it currently does not offer dividends to attract income-seeking investors.
- Investor Choice: For turnaround investors, Pfizer may represent a superior option, particularly for those who value dividends, as Teva's business overhaul presents greater challenges compared to the typical industry headwinds Pfizer is navigating.
See More
Druckenmiller Cuts Pharma and Semiconductor Holdings
- Selling Top Performers: In his latest 13F filing, Druckenmiller reduced his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% cut, and also sold 222,000 shares of Taiwan Semiconductor Manufacturing (TSMC), a 29% reduction, indicating a cautious outlook on the future performance of these stocks.
- Teva's Financial Improvement: Under CEO Richard Francis, Teva has focused on high-margin novel drug development, leading to significant sales growth, with its stock price doubling since Druckenmiller's initial investment in Q3 2024, reflecting improved financial flexibility after years of cost-cutting and asset sales.
- TSMC's AI Advantage: TSMC, the world's leading chip fabricator, has also seen its stock price double since Druckenmiller opened a position, benefiting from its chip technology being a staple in AI-accelerated data centers, highlighting its critical role in the rapidly evolving tech landscape.
- New Investment Focus: Druckenmiller's 13F report revealed a purchase of 5,495,600 shares of the State Street Financial Select Sector SPDR ETF (XLF), making it his fund's second-largest holding, signaling optimism about the U.S. economic recovery, despite the Federal Reserve's easing cycle since September 2024, which could impact financial stocks' performance.
See More
Druckenmiller Reduces Stakes in Pharma and Semiconductor Stocks
- Pharmaceutical Stake Reduction: Druckenmiller cut his stake in Teva Pharmaceuticals by 10,719,065 shares, a 65% reduction, reflecting a profit-taking strategy after significant stock appreciation, indicating a cautious outlook on the pharmaceutical sector's future.
- Semiconductor Stake Cut: He also reduced his position in Taiwan Semiconductor by 222,000 shares, a 29% decrease, likely due to concerns over the stock's overheated performance amid the AI revolution, showcasing his sensitivity to market fluctuations.
- ETF Investment Increase: Druckenmiller purchased 5,495,600 shares of the State Street Financial Select Sector SPDR ETF, making it the fund's second-largest holding, signaling optimism about the U.S. economic recovery, particularly as rising interest rates could enhance financial sector profitability.
- Portfolio Dynamics: With an average holding period of 7.5 months for securities in his portfolio, Druckenmiller demonstrates a flexible investment strategy and rapid responsiveness to market changes, suggesting a keen awareness of future market trends.
See More
Teva and Blackstone Reach $400 Million Strategic Funding Agreement
- Strategic Funding Agreement: Teva Pharmaceuticals has entered into a $400 million strategic funding agreement with Blackstone Life Sciences, with funds allocated over four years to support the clinical development of duvakitug, reflecting confidence in the drug's potential.
- Clinical Development Support: Blackstone Life Sciences will finance ongoing and future development costs for duvakitug, and upon FDA approval, Teva will pay milestone payments to Blackstone, further advancing the product's path to market.
- Market Potential: Duvakitug is a human monoclonal antibody targeting TL1A, currently in phase 3 clinical studies for ulcerative colitis and Crohn's disease, and successful commercialization could meet the urgent market demand for new therapies.
- Collaborative Development: Teva is co-developing duvakitug with Sanofi under a separate agreement, and subject to regulatory approval, will co-commercialize the asset, enhancing market competitiveness and expanding market share.
See More
